Dynavax Technologies (Nasdaq:
DVAX)
A clinical-stage biopharmaceutical company, that discovers and
develops novel products to prevent and treat infectious diseases. The
Company's lead product candidate is HEPLISAV, a Phase 3 investigational
adult hepatitis B vaccine designed to provide more rapid and increased
protection with fewer doses than current licensed vaccines.
More
on DVAX here
Achillion Pharmaceuticals (Nasdaq:
ACHN)
An innovative pharmaceutical company dedicated
to bringing important new treatments to patients with infectious disease.
The company's proven discovery and development teams have advanced multiple
product candidates with novel mechanisms of action. Achillion is focused on
solutions for the most challenging problems in infectious disease – HCV,
HIV and resistant bacterial infections.
More
on ACHN here
Wizzard Software (AMEX:
WZE)
The
industry's leading podcasting network, the Company announced that it
recorded an unprecedented 1.4 billion podcast download requests in 2009.
Wizzard Media, through its premier podcast-hosting service Libsyn, received
an average of 3.77 million requests for podcast episodes per day in 2009. On
average, 23 minutes per episode equates to almost 1.5 million hours of
programming distributed worldwide every day.
Wizzard provides publishing and distribution services
to podcasters as well as monetization services.
Podcasts are a means for independent and
professional content creators to publish audio and video shows for the world
to enjoy over the Internet or on mp3 players, such as the Apple iPod, iPhone and the Microsoft
Zune. Podcasting is a relatively new
phenomenon, but Wizzard Media collectively broadcasts millions of podcast
downloads per day through media aggregators like Apple's iTunes and
Microsoft's Zune Marketplace.
More
on WZE here
Micrus Endovascular (Nasdaq:
MEND)
Develops, manufactures and markets
implantable and disposable medical devices for use in the treatment of
cerebral vascular diseases. Micrus products are used by interventional
neuroradiologists, interventional neurologists and endovascularly trained
neurosurgeons to treat both cerebral aneurysms responsible for hemorrhagic
stroke and intracranial atherosclerosis, which may lead to ischemic
stroke.
The company has operations in the Americas,
Europe, and the Asia Pacific.
More
on MEND here